| Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| private:chipdxllc-2 | 1559734 | May 23rd, 2019 12:00AM | ChipDX LLC | 20 | 0.00 | Open | Medical Devices | May 23rd, 2019 01:34PM | May 23rd, 2019 01:34PM | ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. | Open | Diagnostic assay development, Personalized medicine, Cancer prognosis prediction, Genomics | Open | PO Box 286874 | New York | NY | US | 10128 | ChipDX LLC | Health Care Equipment & Services | ||
| private:chipdxllc-2 | 1559734 | Nov 7th, 2017 12:00AM | ChipDX LLC | 18 | 0.00 | Open | Medical Devices | Nov 7th, 2017 06:26PM | Nov 7th, 2017 06:26PM | ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. | ChipDX LLC | Health Care Equipment & Services | ||||||||||
| private:chipdxllc-2 | 1559734 | Nov 1st, 2017 12:00AM | ChipDX LLC | 18 | 0.00 | Open | Medical Devices | Nov 1st, 2017 06:01AM | Nov 1st, 2017 06:01AM | ChipDX develops and delivers novel multi-gene diagnostic and prognostic assays for oncology. The aim of the company is to increase access to advanced, well-validated predictive and prognostic assays, through collaborations with existing diagnostic service providers and also through our modular, online delivery system: www.ChipDX.com Currently we have created tests for: - Assessing the quality of a patients genomic profile to ensure reliable, accurate results - Characterizing metastatic or poorly differentiated tumors, and - Predicting recurrence in patients diagnosed with early stage breast or colon cancer. Other novel assays are in active development and we are keen to form strategic collaborations with appropriate organizations and individuals to further validate and market those already developed. Related publications: Van Laar, R.K., An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Br J Cancer. Van Laar, R. K. (In Press). "Design and multi-series validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival." J Mol Diagn. | ChipDX LLC | Health Care Equipment & Services |